On August 27, 2020 Seattle Genetics, Inc. (Nasdaq:SGEN) reported the presentation of new data from its broad pipeline of marketed and investigational therapies at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Virtual Congress 2020, taking place September 19-21 (Press release, Seattle Genetics, AUG 27, 2020, View Source [SID1234564104]). Twelve abstracts, including a late-breaking abstract accepted for oral presentation featuring data from the positive tisotumab vedotin phase 2 innovaTV 204 clinical trial in recurrent or metastatic cervical cancer, will highlight the company’s continued progress in advancing research in cancers that have a significant unmet need.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"At the ESMO (Free ESMO Whitepaper) Virtual Congress, we will be sharing important updates from our broad oncology portfolio of both marketed and investigational therapies, including an oral presentation of full data from the phase 2 trial evaluating tisotumab vedotin in recurrent or metastatic cervical cancer," said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. "In addition, we will present data describing real-world outcomes for patients with HER2-positive breast cancer with brain metastases, as well as additional analyses of the impact of TUKYSA on clinical outcomes and quality of life for patients in the HER2CLIMB trial. As illustrated by several trials in progress presentations, we continue to advance the development of our programs across a range of unmet medical needs."
The abstract titles published in advance of the ESMO (Free ESMO Whitepaper) Congress can be found here. All data presentations will be available via on-demand view starting on Thursday, September 17, 2020.
Details of Key Seattle Genetics Presentations at ESMO (Free ESMO Whitepaper) Virtual Congress 2020:
Abstract Title
Abstract # / Presentation #
Presentation
Type / Date
Presenter
Completed Clinical Trials
Tisotumab Vedotin
Tisotumab vedotin (TV) in previously treated recurrent or metastatic cervical cancer (r/mCC): results from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study
#3435/#LBA32
Late-breaking oral presentation / Monday, Sept. 21 at 17:04 CET
RL. Coleman
Tucatinib (TUKYSA)
Impact of Tucatinib on Health-Related Quality of Life (HRQoL) in Patients with HER2+ Metastatic Breast Cancer (MBC) with and without Brain Metastases (BM)
#2067/#275O
Oral presentation / Monday, Sept. 21 at 12:42 CET
V. Mueller
Impact of Tucatinib on Progression-Free Survival in Patients with HER2+ Metastatic Breast Cancer and Brain Metastases
#2073/#293P
Poster presentation / Thursday, Sept. 17
T. Bachelot
Real-world outcomes among HER2+ metastatic breast cancer patients with brain metastases
#4262/#308P
Poster presentation / Thursday, Sept. 17
N. Lindegger
Physiologically Based Pharmacokinetic (PBPK) Modeling of the Central Nervous System (CNS) Pharmacokinetics of Tucatinib in Patients with Breast Cancer Brain Metastasis
#3068/#295P
Poster presentation / Thursday, Sept. 17
A. Lee
Enfortumab Vedotin (PADCEV)
EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
#2223/#746P
Poster presentation / Thursday, Sept. 17
P. O’Donnell
Trials-in-Progress
Enfortumab Vedotin (PADCEV)
Study EV-302: A 3-arm, open-label, randomized phase 3 study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer
#2065/#798TiP
Poster presentation / Thursday, Sept. 17
M. van der Heijden
Tucatinib (TUKYSA)
MOUNTAINEER: Open-Label, Phase 2 Study of Tucatinib Combined with Trastuzumab for HER2-Positive Metastatic Colorectal Cancer
#2070/#523TiP
Poster presentation / Thursday, Sept. 17
J. Strickler
HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
#2068/#353TiP
Poster presentation / Thursday, Sept. 17
S. Hurvitz
Other Investigational Therapies
innovaTV 208: New Weekly Dosing Cohort in the Phase 2 Study of Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer
#2221/#882TiP
Poster presentation / Thursday, Sept. 17
SV. Blank
SGNLVA-002: Single arm, open-label, phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
#2075/#357TiP
Poster presentation / Thursday, Sept. 17
J. Cortez
SGNTGT-001: A phase 1 study of SGN‑TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies
#2076/#1074TiP
Poster presentation / Thursday, Sept. 17
E. Garralda